Salarius Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $5,899,910 | $12,106,435 |
| Grants receivable from CPRIT | — | 1,610,490 |
| Prepaid expenses and other current assets | 619,763 | 803,373 |
| Total current assets | 6,519,673 | 14,520,298 |
| Other assets | 66,850 | 130,501 |
| Total assets | $6,586,523 | $14,650,799 |
| Liabilities and stockholders' equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $602,853 | $2,858,330 |
| Accrued expenses and other current liabilities | 406,745 | 1,407,861 |
| Notes payable | 289,643 | $— |
| Total liabilities | $1,299,241 | $4,266,191 |
| Commitments and contingencies (NOTE 5) | ||
| Stockholders' equity (deficit): | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued or outstanding | — | — |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 3,938,433 and 2,255,899 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 393 | 225 |
| Additional paid-in capital | 81,634,730 | 74,189,531 |
| Accumulated deficit | (76,347,841) | (63,805,148) |
| Total stockholders' equity | 5,287,282 | 10,384,608 |
| Total liabilities and stockholders' equity | $6,586,523 | $14,650,799 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.